Targeting lung cancer to enhance immune response
Dual targeting of cGAS-STING and splicing to prime lung cancer immunogenicity
This study is exploring a new way to help people with non-small cell lung cancer, especially those with certain genetic changes, by using special treatments to boost their immune system and make their tumors more responsive to current therapies.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Brigham and Women's Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-10914651 on NIH RePORTER |
What this research studies
This research investigates a novel approach to improve treatment outcomes for patients with non-small cell lung cancer (NSCLC), particularly those with specific genetic mutations. The study aims to restore the immune response against lung cancer by using epigenetic agents to enhance the expression of a protein called STING, followed by targeted inhibition of a protein involved in cell division. By validating this strategy in clinical samples, the research seeks to determine if it can make resistant tumors more responsive to existing immunotherapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small cell lung cancer, particularly those with KRAS and STK11 mutations.
Not a fit: Patients with other types of lung cancer or those who do not have the specific genetic mutations being targeted may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly improve treatment options and survival rates for patients with resistant forms of lung cancer.
How similar studies have performed: Other research has shown promising results using similar approaches to enhance immune responses in cancer treatment, indicating potential for success in this study.
Where this research is happening
Boston, United States
- Brigham and Women's Hospital — Boston, United States (Active)
Researchers
- Principal investigator: Gedeon, Patrick C — Brigham and Women's Hospital
- Study coordinator: Gedeon, Patrick C
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.